Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on June 18, 2014. The report addresses a specific corporate event under Item 8.01 (Other Events) regarding the presentation of clinical trial data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates and does not contain financial statements.
Material Changes
There are no financial material changes reported. The significant event is the presentation of final data from the NSI-189 Phase Ib study in major depressive disorder at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida.
Outlook, Risks, and Management Commentary
- Management Commentary: The company announced the availability of final data for its NSI-189 Phase Ib study.
- Reference Material: An abstract of the presented information is available on page 73 of the ASCP abstract book, and a press release is attached as Exhibit 99.01.
- Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trial outcomes.
Investor Verification Checklist
- Verify the specific results of the NSI-189 Phase Ib study by reviewing the attached press release (Exhibit 99.01).
- Confirm the clinical significance of the data presented at the ASCP Annual Meeting by consulting the abstract on page 73 of the referenced document.
- Note that this filing contains no financial data; investors should refer to the company's most recent 10-Q or 10-K for financial status.